PI3K/Akt Signaling in Neurodegeneration

PI3K/Akt Signaling in Neurodegeneration

Overview

The PI3K/Akt signaling pathway represents one of the most critical pro-survival cascades in the central nervous system, regulating neuronal survival, metabolism, synaptic plasticity, and protein homeostasis[@akt2024]. Dysregulation of this pathway significantly contributes to neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and other neurodegenerative disorders[@pikakt2023]. The pathway serves as a crucial intersection between neurotrophic factor signaling and cellular survival mechanisms, making it a central focus for understanding neurodegeneration and developing therapeutic interventions[@akt2022].

Akt (also known as Protein Kinase B, PKB) is a serine/threonine protein kinase that promotes cell survival through multiple downstream effectors. The PI3K/Akt signaling cascade is one of the most important cell survival pathways in neurons, linking extracellular growth factor signals to intracellular survival programs. This pathway is particularly important in the central nervous system, where post-mitotic neurons require robust survival signaling to maintain function throughout the lifespan.

Pathway Architecture and Molecular Components

Class I PI3K Isoforms

The class I PI3K isoforms are heterodimers consisting of a p85 regulatory subunit and a p110 catalytic subunit[@class2024]:

PI3K/Akt Signaling in Neurodegeneration

Overview

The PI3K/Akt signaling pathway represents one of the most critical pro-survival cascades in the central nervous system, regulating neuronal survival, metabolism, synaptic plasticity, and protein homeostasis[@akt2024]. Dysregulation of this pathway significantly contributes to neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and other neurodegenerative disorders[@pikakt2023]. The pathway serves as a crucial intersection between neurotrophic factor signaling and cellular survival mechanisms, making it a central focus for understanding neurodegeneration and developing therapeutic interventions[@akt2022].

Akt (also known as Protein Kinase B, PKB) is a serine/threonine protein kinase that promotes cell survival through multiple downstream effectors. The PI3K/Akt signaling cascade is one of the most important cell survival pathways in neurons, linking extracellular growth factor signals to intracellular survival programs. This pathway is particularly important in the central nervous system, where post-mitotic neurons require robust survival signaling to maintain function throughout the lifespan.

Pathway Architecture and Molecular Components

Class I PI3K Isoforms

The class I PI3K isoforms are heterodimers consisting of a p85 regulatory subunit and a p110 catalytic subunit[@class2024]:

PI3Kα (PIK3CA):

• Contains p110α catalytic subunit
• Broadly expressed and important for growth factor signaling
• Critical for insulin and IGF-1 signaling

• Contains p110β catalytic subunit
• Primarily expressed in blood cells and some neuronal populations
• Important for G protein-coupled receptor signaling

• Predominantly in immune cells
• Involved in inflammatory responses
• Mediates chemokine receptor signaling

• Leukocyte-specific isoform
• Limited neuronal expression
• Important in microglial function

Akt Isoforms

Akt exists in three isoforms with distinct tissue distributions[@akt2024a]:

Akt1 (PKBα):

• Widely expressed
• Important for embryonic development
• Primary mediator of cell survival signals

• Important for metabolic functions
• Insulin signaling in peripheral tissues
• Limited role in neurons

• Highly expressed in brain
• Crucial for neuronal function
• Cognitive processing and synaptic plasticity

Downstream Effectors

GSK-3β (Glycogen Synthase Kinase-3 Beta):
Akt phosphorylates GSK-3β at Ser9, inhibiting its kinase activity[@gsk2023]. This provides a key link between PI3K/Akt signaling and tau phosphorylation. GSK-3β dysregulation contributes to both amyloid and tau pathology in AD. The kinase phosphorylates tau at multiple sites associated with NFT formation.

BAD (BCL2-Associated Agonist of Cell Death):
Akt phosphorylates BAD at Ser136, promoting its sequestration by 14-3-3 proteins[@bad2023]. This prevents BAD from inhibiting anti-apoptotic BCL-2 proteins. Neuronal survival requires BAD inactivation through phosphorylation.

FOXO Transcription Factors:
Akt phosphorylates FOXO1 and FOXO3a, promoting their cytoplasmic retention[@foxo2009]. Phosphorylated FOXOs are sequestered in the cytoplasm by 14-3-3 proteins. This prevents transcription of pro-apoptotic genes including BIM, PUMA, and FasL.

mTOR (mammalian Target of Rapamycin):
Akt activates mTORC1 through multiple mechanisms including TSC2 inhibition and PRAS40 phosphorylation[@mtor2024]. mTORC1 regulates protein synthesis through S6K1 and 4E-BP1. mTORC1 also inhibits autophagy, linking growth factor signaling to protein homeostasis.

CREB (cAMP Response Element-Binding Protein):
Akt can phosphorylate and activate CREB, promoting expression of survival genes[@creb2000]. CREB-mediated transcription is important for neuronal plasticity and memory. BDNF expression is partly regulated by CREB.

PI3K/Akt in Alzheimer's Disease

Dysregulation in AD Brain

Multiple alterations in the PI3K/Akt pathway characterize Alzheimer's disease brain[@akt2023]:

Reduced Akt Signaling:

• Decreased Akt phosphorylation at both Thr308 and Ser473 in AD hippocampus
• Impaired PI3K activity in cortical and hippocampal regions
• Reduced growth factor signaling through TrkB and IGF-1 receptors

• Increased PTEN expression in AD brain correlates with reduced PIP3 levels
• PTEN mutations or inhibitors protect against amyloid-β toxicity in models
• PTEN is a major negative regulator of the pathway

• Reduced BDNF levels in AD hippocampus and cortex
• Impaired IGF-1 signaling contributes to neuronal vulnerability
• Decreased neurotrophic support exacerbates neurodegeneration

Connection to AD Pathogenesis

Amyloid-β Effects:
Amyloid-β (Aβ) impairs PI3K/Akt signaling through multiple mechanisms[@amyloid2008]:

• Aβ oligomers inhibit PI3K activity at synapses
• Synaptic PI3K/Akt dysfunction contributes to memory deficits
• Aβ-induced oxidative stress inactivates Akt signaling

• Akt regulates GSK-3β activity, which directly phosphorylates tau
• Tau pathology disrupts postsynaptic signaling including PI3K/Akt
• Hyperphosphorylated tau may sequester Akt, impairing its function

• Akt regulates AMPA receptor trafficking during LTP
• Synaptic PI3K/Akt signaling is required for memory consolidation
• Synaptic deficits in AD correlate with PI3K/Akt dysregulation

Therapeutic Potential

Akt Activators:
Direct and indirect strategies to activate Akt are being explored[@akt2022a]:

• Phosphatase inhibitors that preserve Akt phosphorylation
• Growth factor mimetics that enhance upstream signaling
• Allosteric Akt activators in development

• Reduces tau phosphorylation and aggregation
• Improves cognitive function in AD models
• Multiple inhibitors in clinical trials for AD and bipolar disorder

• Induction of autophagy to clear protein aggregates
• Enhanced clearance of Aβ through autophagy
• Potential for combination with other therapeutic approaches

PI3K/Akt in Parkinson's Disease

Dopaminergic Neuron Survival

The PI3K/Akt pathway is particularly important for dopaminergic neuron survival[@origins2017]:

• High basal PI3K/Akt activity in substantia nigra pars compacta (SNc)
• Dopaminergic neurons are vulnerable when pathway is compromised
• Growth factor dependence makes these neurons susceptible to PI3K/Akt dysfunction

GDNF Signaling

GDNF provides critical survival signaling for dopaminergic neurons[@gdnf2019]:

• GDNF activates RET receptor tyrosine kinase
• PI3K/Akt signaling is the primary survival pathway downstream of RET
• GDNF and related factors have been tested clinically in PD patients

α-Synuclein Connection

α-Synuclein pathology affects PI3K/Akt signaling[@synuclein2022]:

• α-Synuclein oligomers impair PI3K/Akt signaling
• Reduced neuronal survival signaling in PD models
• PI3K/Akt dysregulation may contribute to α-synuclein propagation

Mitochondrial Function

PI3K/Akt regulates mitochondrial function and dynamics[@mitochondrial2022]:

• Akt promotes glucose uptake and mitochondrial biogenesis
• Mitochondrial dynamics are regulated through Akt signaling
• Anti-apoptotic effects include regulation of BCL-2 family proteins

PI3K/Akt in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

PI3K/Akt signaling alterations in ALS include[@pikakt2023b]:

• Motor neuron vulnerability related to growth factor dependence
• Mutations in PI3K pathway genes identified in familial ALS
• Growth factor therapy approaches showing promise in models

Huntington's Disease

Mutant huntingtin affects PI3K/Akt signaling[@huntingtons2023]:

• Impaired PI3K/Akt signaling contributes to neuronal dysfunction
• Therapeutic targeting of the pathway shows benefits in models
• Cross-talk with mutant huntingtin pathology

Multiple Sclerosis

The pathway affects oligodendrocyte survival and myelin repair[@pikakt2022]:

• PI3K/Akt promotes oligodendrocyte progenitor cell survival
• Myelin repair mechanisms require Akt signaling
• Immune modulation through PI3K/Akt affects disease course

Autophagy and Protein Homeostasis

mTORC1-Dependent Autophagy

Akt activates mTORC1, which regulates autophagy[@role2003]:

• mTORC1 inhibits autophagy initiation through ULK1 phosphorylation
• Autophagy inhibition by mTORC1 contributes to protein aggregate accumulation
• Dysregulated autophagy is a hallmark of neurodegenerative diseases

Therapeutic Implications

Modulating autophagy through PI3K/Akt has therapeutic potential[@autophagy2022]:

• mTOR inhibitors (rapamycin, everolimus) induce autophagy
• PI3K inhibitors have complex effects, depending on isoform selectivity
• Autophagy enhancers targeting downstream nodes show promise

Therapeutic Approaches

Pharmacological Strategies

| Compound | Target | Status | Notes |
|----------|--------|--------|-------|
| GSK-3 inhibitors | GSK-3β | Clinical trials | AD, bipolar disorder |
| Rapamycin | mTORC1 | Approved | Immunosuppression, repurposed |
| Akt inhibitors | Akt | Clinical trials | Cancer applications |
| PI3K modulators | PI3K | Preclinical | Pathway modulation |

Growth Factor Therapies

Multiple growth factor approaches target PI3K/Akt signaling[@growth2023]:

• BDNF delivery through various routes
• IGF-1 therapy in clinical trials
• GDNF for PD has reached clinical testing

Gene Therapy

Viral vector-mediated gene delivery shows promise[@aavmediated2024]:

• AAV-mediated Akt1 overexpression protects neurons
• Growth factor expression via viral vectors
• Combination approaches targeting multiple nodes

Combination Approaches

Rational combinations are being developed:

• PI3K/Akt modulation with amyloid-targeting
• mTOR inhibition with tau-targeting
• Growth factor delivery with anti-inflammatory approaches

Research Frontiers

Biomarker Development

PI3K/Akt pathway biomarkers under development[@biomarkers2024]:

• Phosphorylated Akt in CSF and blood
• Downstream effector phosphorylation status
• Pathway activity scores from gene expression

Precision Medicine Approaches

Genetic variations affecting pathway activity:

• PTEN polymorphisms modify AD risk
• Akt isoforms differentially affect disease subtypes
• Personalized targeting based on pathway status

Novel Therapeutic Modalities

Emerging strategies include[@therapeutic2023]:

• Brain-penetrant Akt activators
• Isoform-selective PI3K modulators
• Allosteric pathway activators

Conclusion

The PI3K/Akt signaling pathway represents a central hub connecting neurotrophic factor signaling to neuronal survival, metabolic regulation, and protein homeostasis. Dysregulation of this pathway contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The pathway's importance is underscored by its multiple connections to key pathological features including amyloid-β toxicity, tau phosphorylation, α-synuclein aggregation, and mitochondrial dysfunction. Therapeutic strategies targeting this pathway, including growth factor therapies, GSK-3 inhibitors, and autophagy modulators, hold promise for disease-modifying treatments in neurodegeneration. Understanding the precise context of PI3K/Akt dysregulation in different neurodegenerative diseases will be essential for developing effective targeted therapies[@ampk2012].

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References